Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Expects $557M from Public Offering

NEW YORK (GenomeWeb News) – Qiagen expects to raise gross proceeds of around $557 million from a public offering of newly issued common shares.

The firm said last night that it will offer 27.5 million shares at a price of $20.25 per share. Qiagen's shares closed at $21.02 in Thursday trade on the Nasdaq.

Qiagen had announced its intention to offer the shares earlier this week, on the same day that it announced it would acquire companion diagnostics firm DxS in a deal worth as much as $130 million. It said that the proceeds from the offering would be used to help fund the acquisition of DxS, as well as for potential future acquisitions, to strengthen its balance sheet, and for general corporate purposes.

Qiagen said that delivery of the shares will take place on Sep. 30, by which date the shares are expected to be trading on the Frankfurt Stock Exchange and the Nasdaq Global Select Market.

Filed under

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.